GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, presented final data from the G-202 Phase I clinical trial yesterday at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA (http://www.aacr.org/home/scientists/meetings--workshops/molecular-targets-and-cancer-therapeutics.aspx). In presenting a poster called, “A First-in-Human, Phase I Clinical Study of G-202, a Thapsigargin-Based Prostate-Specific Membrane Antigen (PSMA)-Activated Prodrug, in Patients with Advanced Solid Tumors,” Dr. Mahalingam reported that 27% of the patients exhibited stable disease and two of the five patients with hepatocellular carcinoma had a prolonged stable disease of more than nine months (nine cycles of treatment).
Help employers find you! Check out all the jobs and post your resume.
